Hepatitis C treatment for people with severe mental illness

Psychosomatics

Volumn 47, Issue 2, 2006, Pages 93-107

  Mistler, Lisa A ^a   Brunette, Mary F ^b   Marsh, Bryan J ^b   Vidaver, Robert M ^b   Luckoor, Ravi ^b   Rosenberg, Stanley D ^b  

^a New Hampshire Dartmouth Psychiatric Research Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT; CITALOPRAM; CORTICOTROPIN; FLUOXETINE; HYDROCORTISONE; KYNURENINE; NORTRIPTYLINE; PAROXETINE; PLACEBO; SEROTONIN; SERTRALINE; TRYPTOPHAN;

ANHEDONIA; ANXIETY DISORDER; APPETITE DISORDER; BRAIN TOXICITY; CLINICAL TRIAL; COGNITIVE DEFECT; DELIRIUM; ELECTROENCEPHALOGRAM; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERALGESIA; INTRAVENOUS DRUG ABUSE; LETHARGY; LISTLESSNESS; MAJOR DEPRESSION; MANIA; MEMORY DISORDER; MENTAL DISEASE; NEURASTHENIA; NEUROPSYCHIATRY; PATIENT EDUCATION; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PSYCHOSIS; REVIEW; SLEEP DISORDER; SUICIDE ATTEMPT;

EID: 33644780945     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.psy.47.2.93     Document Type: Review

References (99)

1. Rosenberg SD, Goodman LA, Osher FC, et al: Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. Am J Public Health 2001; 91:31-37
2. Meyer JM: Prevalence of hepatitis A, hepatitis B, and HIV among hepatitis C-seropositive state hospital patients: results from Oregon State Hospital. J Clin Psychiatry 2003; 64:540-545
3. Klinkenberg WD, Caslyn RJ, Morse GA, et al: Prevalence of human immunodeficiency virus, hepatitis B, and hepatitis C among homeless persons with co-occurring mental illness and substance-use disorders. Compr Psychiatry 2003; 44:293-302
4. Essock SM, Dowden S, Constantine NT, the Five-Site Health and Risk Study Research Committee, et al: Blood-borne infections and persons with mental illness: risk factors for HIV, hepatitis B, and hepatitis C among persons with severe mental illness. Psychiatr Serv 2003; 54:836-841
5. Osher FC, Goldberg R, Goodman LA, et al: Hepatitis C and individuals with serious mental illness. Psychiatr Ann 2003; 33:394-400
6. Rosenberg SD, Swanson JW, Wolford GL, et al: Blood-borne infections and persons with mental illness: the Five-Site Health and Risk Study of Blood-Borne Infections Among Persons With Severe Mental Illness. Psychiatr Serv 2003; 54:827-835
7. Di Bisceglie AM, Hoofnagle JH: Optimal therapy of hepatitis C. Hepatology 2002; 36(suppl 1):S121-127
8. Chander G, Sulkowski MS, Jenckes MW, et al: Treatment of chronic hepatitis C: a systematic review. Hepatology 2002; 36(suppl 1):S135-144
9. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C 2002 (June 10-12, 2002). Gastroenterology 2002; 123:2082-2099
10. Dept. of Veterans Affairs: Hepatitis C Virus (HCV) Testing and Prevention Counseling Guidelines for VA Health Care Practitioners, Centers of Excellence, Department of Veterans Affairs, 2001
11. Fried M, Schiffman M, Reddy R, et al: Pegylated (40kDa) (PEGASYS) interferon alfa-2a in combination with ribavirin: efficacy and safety results from a phase III, randomized, actively controlled, multicenter study (abstract). Gastroenterology 2001; 120:A55
12. Manns M, McHutchinson J, Gordon S, et al: PEG-interferon alfa-2B plus ribavirin compared with interferon alfa-2B plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358(958-965)
13. Grob JJ, Dreno B, de la Salmoniere P, et al: Randomised trial of interferon alpha-2A as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases: French Cooperative Group on Melanoma (comment). Lancet 1998; 351:1905-1910
14. Bernstein D, Kleinman L, Barker C, et al: Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002; 35:704-708
15. Fleming CA, Craven DE, Thornton D, et al: Hepatitis C virus and human immunodeficiency virus co-infection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 2003; 36:97-100
16. Strader DB: Understudied populations with hepatitis C. Hepatology 2002; 36:5226-5236
17. Taylor LE, Costello T, Alt E, et al: Psychiatric illness and illicit drugs as barriers to hepatitis C treatment among HIV/hepatitis virus co-infected individuals. AIDS 2002; 16:1700-1701
18. Capuron L, Bluthe RM, Dantzer R: Cytokines in clinical psychiatry (comment). Am J Psychiatry 2001; 158:1163-1164
19. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Revised. Washington, DC, American Psychiatric Association, 1994
20. Malaguarnera M, Di Fazio I, Restuccia S, et al: Interferon alpha-induced depression in chronic hepatitis C patients: comparison between different types of interferon alpha. Neuropsychobiology 1998; 37:93-97
21. Davis GL, Balart LA, Schiff ER, et al: Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial: Hepatitis Interventional Therapy Group. N Engl J Med 1989; 321:1501-156
22. McDonald E, Mann A, Thomas H: Interferons as mediators of psychiatric morbidity. Lancet 1987; 21:1175-1178
23. Caraceni A, Ganged L, Martini C, et al: Neurotoxicity of interferon-alpha in melanoma therapy: results from a randomized, controlled trial. Cancer 1998; 83:482-489
24. Bonaccorso S, Marino V, Biondi M, et al: Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord 2002; 72:237-241
25. Adler-Cohen M, Jacobson J: Maximizing life's potentials in AIDS: a psychopharmacologic update. Gen Hosp Psychiatry 2000; 22:375-388
26. Pariante CM, Orru MG, Baita A, et al: Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet 1999; 354:131-132
27. Capuron L, Ravaud A: Prediction of the depressive effects of interferon-alfa therapy by the patient's initial affective state (comment). N Engl J Med 1999; 340:1370
28. Adams F, Quesada JR, Gutterman JU: Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. JAMA 1984; 252:938-941
29. Hauser P, Khosla J, Aurora H, et al: A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002; 7:942-947
30. Hunt CM, Dominitz JA, Bute BP, et al: Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. Digest Dis Sci 1997; 42:2482-246
31. Scalori A, Apale P, Panizzuti F, et al: Depression during interferon therapy for chronic viral hepatitis: early identification of patients at risk by means of a computerized test. Eur J Gastroenterol Hepatol 2000; 12:505-509
32. Renault PF, Hoofnagle JH, Park Y, et al: Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 1987; 147:1577-1580
33. Kraus MR, Schafer A, Scheurlen M: Paroxetine for the prevention of depression induced by interferon alfa (comment). New Engl J Med 2001; 345:375-376
34. Mapou RL, Law WA, Wagner K, et al: Neuropsychological effects of interferon alfa-N3 treatment in asymptomatic human immunodeficiency virus-1-infected individuals. J Neuropsychiatry Clin Neurosci 1996; 8:74-81
35. Mulder R, Ang M, Chapman B, et al: Interferon treatment is not associated with a worsening of psychiatric symptoms in patients with hepatitis C. J Gastroenterol Hepatol 2000; 15:300-303
36. Davis GL, Esteban-Mur R, Rustgi V, et al: Interferon alfa-2B alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group (comment). N Engl J Med 1998; 339:1493-149
37. Fried MW, Peter J, Hoots K, et al: Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2B and ribavirin. Hepatology 2002; 36(4:Pt 1):967-972
38. Guilhot F, Chastang C, Michallet M, et al: Interferon alfa-2B combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group (comment). N Engl J Med 1997; 337:223-229
39. Hensley ML, Peterson B, Silver RT, et al: Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2B and low-dose cytarabine for chronic myelogenous leukemia: Analysis of Cancer and Leukemia Group (B 9013). J Clin Oncology 2000; 18:1301-138
40. Kirkwood JM, Resnick GD, Cole BF: Efficacy, safety, and risk-benefit analysis of adjuvant interferon alfa-2B in melanoma. Semin Oncol 24 1997; (1:suppl4):S16-S23
41. McHutchison JG, Gordon SC, Schiff ER, et al: Interferon alfa-2B alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group (comment). N Engl J Med 1998; 339:1485-1492
42. Donnelly S: Patient-management strategies for interferon alfa-2B as adjuvant therapy of high-risk melanoma. Oncol Nurs Forum 1998;25:921-927
43. Hosoda S, Takimura H, Shibayama M, et al: Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis. Psychiatry Clin Neurosci 2000; 54:565-572
44. Van Thiel DH, Friedlander L, Molloy PJ, et al: Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness. Eur J Gastroenterol Hepatol 1995; 7:165-168
45. Musselman DL, Lawson DH, Gumnick JF, et al: Paroxetine for the prevention of depression induced by high-dose interferon-alfa. N Engl J Med 2001; 344:961-966
46. Grassi L, Mondardini D, Pavanati M, et al: Suicide probability and psychological morbidity secondary to HIV infection: a control study of HIV-seropositive, hepatitis C virus (HCV)-seropositive, and HIV/HCV-seronegative injecting drug users. J Affect Disord 2001;64:195-202
47. Fattovich G, Giustina G, Favarato S, et al: A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24:38-47
48. Janssen HL, Brouwer JT, van der Mast RC, et al: Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 1994; 21:241-243
49. Capuron L, Ravaud A, Dantzer R: Timing and specificity of the cognitive changes induced by interleukin-s and interferon-alpha in cancer patients. Psychosom Med 2001; 63:376-386
50. Otsubo T, Miyaoka H, Kamijima K, et al: Depression during interferon therapy in chronic hepatitis C patients: a prospective study. Seishin Shinkeigaku Zasshi: Psychiatria et Neurologia Japonica 1997; 99:101-127
51. Miyaoka H, Otsubo T, Kamijima K, et al: Depression from interferon therapy in patients with hepatitis C. Am J Psychiatry 1999; 156:1120
52. Bonaccorso S, Marino V, Puzella A, et al: Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002; 22:86-90
53. Castera L, Zigante F, Bastie A, et al: Incidence of interferon-alfa- induced depression in patients with chronic hepatitis C. Hepatology 2002; 35:978-979
54. Schaefer M, Schmidt F, Fowaczny C, et al: Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37:443-451
55. Hauser P, Soler R, Reed S, et al: Prophylactic treatment of depression induced by interferon-alpha. Psychosomatics 2000; 41:439-441
56. Ho S, Nguyen H, Tetrick L, et al: Influence of psychiatric diagnosis on interferon-alpha treatment for chronic hepatitis C in a veteran population. Am J Gastroenterol 2001; 96:157-164
57. Obhrai J, Hall Y, Anand BS: Assessment of fatigue and psychologic disturbances in patients with hepatitis C virus infection. J Clin Gastroenterol 2001; 32:413-417
58. Belville-Robertson T: Neuropsychiatric status of 100 naive chronic hepatitis C patients ready to begin interferon-based treatment, in Schering Hepatitis Investigators' Network VI. Edited by Schering-Plough. Orlando, FL, 2002
59. Forton DM, Thomas HC, Murphy CA, et al: Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002; 35:433-439
60. Kraus MR, Schafer A, Csef H, et al: Emotional state, coping styles, and somatic variables in patients with chronic hepatitis C. Psychosomatics 2000; 41:377-384
61. Silvestre AJ, Gehl MB, Encandela J, et al: A participant-observation study using actors at 30 publicly funded HIV counseling and testing sites in Pennsylvania. Am J Public Health 2000; 90:1096-1109
62. Okanoue T, Sakamoto S, Itoh Y, et al: Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25:283-291
63. Iancu I, Sverdlik A, Dannon PN, et al: Bipolar disorder associate with interferon-alpha treatment. Postgrad Med J 1997; 73:834-83
64. Bozikas V, Petrikis P, Balla A, et al: An interferon-alpha-induce psychotic disorder in a patient with chronic hepatitis C. Eur Psychiatry 2001; 16:136-137
65. Kanno A, Yamada M, Abe M, et al: A case of interferon-alpha induced manic psychosis in chronic hepatitis C. Tohuku Journal of Experimental Medicine 1999; 187:79-82
66. Kamei S, Sakai T, Matsuura M, et al: Alterations of quantitative EEG and Mini-Mental State Exam in interferon-alpha-treated hepatitis C. Eur Neurol 2002; 48:102-107
67. Greenberg DB, Jonasch E, Gadd MA, et al: Adjuvant therapy of melanoma with interferon-alpha-2B is associated with mania and bipolar syndromes. Cancer 2000; 89:356-362
68. Strite D, Valentine AD, Meyers CA: Manic episodes in two patients treated with interferon alpha. J Neuropsychiatry Clin Neurosci 1997; 9:273-276
69. Nozaki O, Takagi C, Takaoka K, et al: Psychiatric manifestation accompanying interferon therapy for patients with chronic hepatitis C: an overview of cases in Japan. Psychiatry Clin Neurosci 1997; 51:175-180
70. Capuron L, Gumnick JF, Musselman DL, et al: Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine-responsiveness of symptom dimensions. Neuropsychopharmacology 2002; 26:643-652
71. Merimsky O, Reider-Groswasser I, Inbar M, et al: Interferon-related mental deterioration and behavioral changes in patients with renal cell carcinoma. Eur J Cancer 1990; 26:596-600
72. Pavol MA, Meyers CA, Rexer JL, et al: Pattern of neurobehavioral deficits associated with interferon-alfa therapy for leukemia (comment). Neurology 1995; 45:947-950
73. Adams F, Fernandez F, Mavligit G: Interferon-induced organic mental disorders associated with unsuspected pre-existing neurologic abnormalities. J Neuro-oncology 1988; 6:355-359
74. Capuron L, Hauser P, Hinze-Seich D, et al: Treatment of cytokine induced depression. Brain Behav Immun 2002; 16:575-580
75. Miller AH: Cytokines and sickness behavior: implications for cancer care and control. Brain Behav Immun 2003; 17(suppl 1):S132-S134
76. Capuron L, Dantzer R: Cytokines and depression: the need for a new paradigm. Brain Behav Immun 2003; 17(suppl 1):S119-S124
77. Capuron L, Raison CL, Musselman DL, et al: Association of exaggerated HPA-axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry 2003; 160:1342-1345
78. Dieperink E, Willenbring M, Ho SB: Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000; 157:867-876
79. Juengling FD, Ebert D, Gut O, et al: Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology 2000; 152:383-389
80. Trask PC, Esper P, Riba M, et al: Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol 2000; 18:2316-2326
81. Van Gool A, Kruit W, Engels F, et al: Neuropsychiatric side effects of interferon-alpha therapy. Pharmacol World Sci 2003; 25:11-20
82. Yates WR, Gleason O: Hepatitis C and depression. Depress Anxiety 1998; 7:188-193
83. Zdilar D, Franco-Bronson K, Buchler N, et al: Hepatitis C, interferon-alfa, and depression (comment). Hepatology 2000; 31:1207-1211
84. Gleason OC, Yates WR, Isbell MD, et al: An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry 2002; 63:194-198
85. Goldman LS: Successful treatment of interferon alfa-induced mood disorder with nortriptyline. Psychosomatics 1994; 35:412-413
86. Schramm TM, Lawford BR, Macdonald GA, et al: Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Austral 2000; 173:359-361
87. Levenson JL, Fallon HJ: Fluoxetine treatment of depression caused by interferon-alpha (comment). Am J Gastroenterol 1993; 88:760-761
88. Valentine AD, Meyers CA, Kling MA, et al; Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol 1998; 25(suppl 1):39-47
89. Dobmeier M, Frick E, Frank S, et al: Schizophrenic psychosis: a contraindication for treatment of hepatitis C with interferon alpha? Pharmacopsychiatry 2000; 33:72-74
90. Sylvester DL: Treating hepatitis C in methadone-maintenance patients: an interim analysis. Drug Alcohol Depend 2002; 67:117-123
91. Drake RE, Mueser KT, et al: A review of treatment for clients with severe mental illness and co-occurring substance-use disorders. Psychosocial Rehabilitation Journal 2004
92. Drake RE, Mercer-McFadden C, Mueser KT, et al: Review of integrated mental health and substance-abuse treatment for patients with dual disorders. Schizophr Bull 1998; 24:589-608
93. Rosenberg S, Goodman L, Osher F, et al: Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. Am J Public Health 2001; 91:31-37
94. Sulkowski MS, Thomas DL: Hepatitis C in the HIV-infected person. Ann Intern Med 2003; 138:197-207
95. Monga HK, Rodriguez-Barradas MC, Breaux K, et al: Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 33:240-247
96. Graham CS, Baden LR, Yu E, et al: Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33:562-569
97. Landau A, Batisse D, Piketty C, et al: Long-term efficacy of combination therapy with interferon-alpha 2B and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS 2001; 15:2149-2155
98. Nasti G, Di Gennaro G, Tavio M: Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2B and ribavirin. AIDS 2001; 15:1783-1787
99. Taylor LE, Schwartzapfel B, Allen S, et al: Extending treatment for HCV infection to HIV-HCV co-infected individuals with psychiatric illness and drug dependence. Clin Infect Dis 2003; 36:1501-1502